• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清 HSP70:一种用于早期检测胰腺癌的新型生物标志物。

Serum HSP70: a novel biomarker for early detection of pancreatic cancer.

机构信息

Division of Gastroenterology, University of Maryland School of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.

出版信息

Pancreas. 2012 May;41(4):530-4. doi: 10.1097/MPA.0b013e3182374ace.

DOI:10.1097/MPA.0b013e3182374ace
PMID:22158074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4193547/
Abstract

OBJECTIVES

Heat shock protein 70 (HSP70) is overexpressed in human pancreatic cancer cell lines. To determine if serum HSP70 levels are elevated in patients with pancreatic cancer and can function as a biomarker for early detection of pancreatic cancer.

METHODS

Study subjects were divided into 3 groups: histologically proven pancreatic cancer (PC; n = 23), chronic pancreatitis (CP; n = 12), and matched normal control subjects (C; n = 10). Serum HSP70 levels were determined using a novel immunoelectrophoresis method developed and validated by the authors. Significance of difference between the groups was analyzed with analysis of variance (ANOVA). Receiver operating characteristic (ROC) curve analysis was performed to discriminate patients with pancreatic cancer from normal controls.

RESULTS

The mean ± SE serum HSP70 levels in the PC, CP, and C groups were 1.68 ± 0.083 ng/mL, 0.40 ± 0.057 ng/mL, and 0.04 ng/mL, respectively. Serum HSP70 levels in the PC group were significantly higher compared with either the CP or C groups (P < 0.01). The sensitivity and specificity of elevated serum HSP70 in the PC group was 74% and 90%, respectively.

CONCLUSIONS

Serum HSP70 levels are significantly increased in patients with pancreatic cancer and may be useful as an additional biomarker for the detection of pancreatic cancer.

摘要

目的

热休克蛋白 70(HSP70)在人胰腺癌细胞系中过度表达。为了确定胰腺癌患者血清 HSP70 水平是否升高,并能否作为胰腺癌早期检测的生物标志物。

方法

研究对象分为 3 组:组织学证实的胰腺癌(PC;n = 23)、慢性胰腺炎(CP;n = 12)和匹配的正常对照组(C;n = 10)。使用作者开发和验证的新免疫电泳法测定血清 HSP70 水平。采用方差分析(ANOVA)分析组间差异的显著性。进行受试者工作特征(ROC)曲线分析,以区分胰腺癌患者和正常对照者。

结果

PC、CP 和 C 组的血清 HSP70 水平均值± SE 分别为 1.68±0.083ng/mL、0.40±0.057ng/mL 和 0.04ng/mL。PC 组血清 HSP70 水平明显高于 CP 或 C 组(P < 0.01)。PC 组中 HSP70 升高的敏感性和特异性分别为 74%和 90%。

结论

胰腺癌患者血清 HSP70 水平显著升高,可作为检测胰腺癌的辅助生物标志物。

相似文献

1
Serum HSP70: a novel biomarker for early detection of pancreatic cancer.血清 HSP70:一种用于早期检测胰腺癌的新型生物标志物。
Pancreas. 2012 May;41(4):530-4. doi: 10.1097/MPA.0b013e3182374ace.
2
Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.生长分化因子 15(GDF-15)浓度联合血清 CA125 水平在胰腺肿块鉴别诊断中优于常用的肿瘤标志物。
Cancer Biomark. 2018 Feb 14;21(3):505-511. doi: 10.3233/CBM-170203.
3
Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.用于区分胰腺导管腺癌与慢性胰腺炎的代谢生物标志物特征
Gut. 2018 Jan;67(1):128-137. doi: 10.1136/gutjnl-2016-312432. Epub 2017 Jan 20.
4
Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.通过结合与胰腺腺癌病理生理学相关的常规临床标志物,改善黄疸和非黄疸胰腺腺癌患者的胰腺腺癌诊断。
PLoS One. 2016 Jan 25;11(1):e0147214. doi: 10.1371/journal.pone.0147214. eCollection 2016.
5
Circulating Heat Shock Protein 70 Is a Novel Biomarker for Early Diagnosis of Lung Cancer.循环热休克蛋白 70 是肺癌早期诊断的新型生物标志物。
Dis Markers. 2018 Aug 29;2018:6184162. doi: 10.1155/2018/6184162. eCollection 2018.
6
Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.三叶因子和 CA19.9:用于早期检测胰腺癌的有前途的标志物组合。
EBioMedicine. 2019 Apr;42:375-385. doi: 10.1016/j.ebiom.2019.03.056. Epub 2019 Apr 5.
7
Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.血清中新蝶呤、组织多肽特异性抗原和 CA19-9 水平在胰腺癌和慢性胰腺炎鉴别诊断中的临床价值。
Pancreatology. 2010;10(6):689-94. doi: 10.1159/000320693. Epub 2011 Jan 18.
8
Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.血清Dickkopf-1是一种用于胰腺癌诊断和预后的新型血清学生物标志物。
Oncotarget. 2015 Aug 14;6(23):19907-17. doi: 10.18632/oncotarget.4529.
9
Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.用于区分自身免疫性胰腺炎、慢性胰腺炎和胰腺导管腺癌的不同病理生理细胞因子谱。
J Transl Med. 2017 Jun 2;15(1):126. doi: 10.1186/s12967-017-1227-3.
10
Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis.胰腺腺癌和慢性胰腺炎中的炎症、肿瘤标志物及白细胞介素-17、-10 和-6 谱。
Dig Dis Sci. 2021 Oct;66(10):3427-3438. doi: 10.1007/s10620-020-06700-w. Epub 2020 Nov 13.

引用本文的文献

1
Modulation of Heat Shock Proteins Levels in Health and Disease: An Integrated Perspective in Diagnostics and Therapy.健康与疾病中热休克蛋白水平的调节:诊断与治疗的综合视角
Cells. 2025 Jun 25;14(13):979. doi: 10.3390/cells14130979.
2
Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma.蛋白质组学荟萃分析揭示了胰腺癌生物标志物研究的新前沿。
Oncogenesis. 2025 Feb 16;14(1):3. doi: 10.1038/s41389-025-00547-4.
3
TLR2-Bound Cancer-Secreted Hsp70 Induces MerTK-Mediated Immunosuppression and Tumorigenesis in Solid Tumors.

本文引用的文献

1
Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology.可溶性 iC3b 作为胰腺腺癌的早期标志物优于 CA19.9 和影像学检查。
J Immunother. 2010 Feb-Mar;33(2):219-24. doi: 10.1097/CJI.0b013e3181bed29f.
2
Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.血清肿瘤标志物 REG4 作为胰腺导管腺癌的诊断标志物。
J Gastroenterol. 2010;45(1):52-9. doi: 10.1007/s00535-009-0114-y. Epub 2009 Sep 30.
3
Cancer statistics, 2009.2009年癌症统计数据。
TLR2结合的癌症分泌型Hsp70诱导实体瘤中MerTK介导的免疫抑制和肿瘤发生。
Cancers (Basel). 2025 Jan 28;17(3):450. doi: 10.3390/cancers17030450.
4
The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy.PCSK9 在癌症发病机制、肿瘤免疫和免疫治疗中的多方面作用。
Med Oncol. 2024 Jul 15;41(8):202. doi: 10.1007/s12032-024-02435-0.
5
Extracellular vesicles in cancer cachexia: deciphering pathogenic roles and exploring therapeutic horizons.癌症恶病质中外泌体:解析致病作用与探索治疗前景。
J Transl Med. 2024 May 27;22(1):506. doi: 10.1186/s12967-024-05266-9.
6
Diversity of extracellular HSP70 in cancer: advancing from a molecular biomarker to a novel therapeutic target.癌症中细胞外HSP70的多样性:从分子生物标志物迈向新型治疗靶点
Front Oncol. 2024 Apr 5;14:1388999. doi: 10.3389/fonc.2024.1388999. eCollection 2024.
7
Patient-Derived Pancreatic Cancer Cells Induce C2C12 Myotube Atrophy by Releasing Hsp70 and Hsp90.患者来源的胰腺癌细胞通过释放 HSP70 和 HSP90 诱导 C2C12 肌管萎缩。
Cells. 2022 Sep 3;11(17):2756. doi: 10.3390/cells11172756.
8
HSP70 and HSP90 in Cancer: Cytosolic, Endoplasmic Reticulum and Mitochondrial Chaperones of Tumorigenesis.癌症中的热休克蛋白70和热休克蛋白90:肿瘤发生的胞质、内质网和线粒体伴侣蛋白
Front Oncol. 2022 Jan 21;12:829520. doi: 10.3389/fonc.2022.829520. eCollection 2022.
9
Ameliorating cancer cachexia by inhibiting cancer cell release of Hsp70 and Hsp90 with omeprazole.通过抑制奥美拉唑治疗癌症恶病质的癌细胞释放 HSP70 和 HSP90
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):636-647. doi: 10.1002/jcsm.12851. Epub 2021 Nov 2.
10
CEACAM6's Role as a Chemoresistance and Prognostic Biomarker for Pancreatic Cancer: A Comparison of CEACAM6's Diagnostic and Prognostic Capabilities with Those of CA19-9 and CEA.癌胚抗原相关细胞黏附分子6(CEACAM6)作为胰腺癌化疗耐药及预后生物标志物的作用:CEACAM6与糖类抗原19-9(CA19-9)和癌胚抗原(CEA)诊断及预后能力的比较
Life (Basel). 2021 Jun 9;11(6):542. doi: 10.3390/life11060542.
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
4
Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.慢性胰腺炎和胰腺癌患者血清热休克蛋白27水平升高。
Pancreas. 2009 May;38(4):422-6. doi: 10.1097/MPA.0b013e318198281d.
5
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.切除性胰腺癌多学科管理后的长期生存
Ann Surg Oncol. 2009 Apr;16(4):836-47. doi: 10.1245/s10434-008-0295-2. Epub 2009 Feb 5.
6
Perioperative management of pancreatic cancer.胰腺癌的围手术期管理
Ann Oncol. 2008 Sep;19 Suppl 7:vii273-8. doi: 10.1093/annonc/mdn450.
7
Heat shock proteins in pancreatic diseases.胰腺疾病中的热休克蛋白
J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S42-5. doi: 10.1111/j.1440-1746.2007.05272.x.
8
Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.新辅助治疗对胰腺腺癌切除术后局部复发的影响。
J Am Coll Surg. 2008 Mar;206(3):451-7. doi: 10.1016/j.jamcollsurg.2007.10.002. Epub 2007 Dec 27.
9
Neoadjuvant therapy for pancreatic cancer.
J Gastrointest Surg. 2008 Sep;12(9):1600-8. doi: 10.1007/s11605-008-0482-2. Epub 2008 Feb 8.
10
Microarray technologies for gene transcript analysis in pancreatic cancer.
Technol Cancer Res Treat. 2008 Feb;7(1):55-9. doi: 10.1177/153303460800700107.